Abstract:CD137 (41-BB, tumor necrosis factor receptor superfamily 9), expressed on activated T cells and NK cells, has gained increased attention as an anti-tumor target because of remarkable clinical efficacy using either a single agent or in combination with other immune checkpoint inhibitors. We constructed CD137 humanized mice based on two different backgrounds, C57BL6 and BALB/c mice, as well as dual-target and triple-target mice crossbred with PD1/PDL1 humanized mice to create an ideal model to study CD137 target drugs. The normal immune cell population in peripheral blood were not affected in CD137 humanized mice, and hCD137 was expressed on T cells after the stimulation with a anti CD3 antibody. We verified the efficacy of anti-CD137 drugs in BALB/c-hCD137 mice inoculated with different cancer cell lines (i.e. CT26, EMT6 and 4T1). The drug Urelumab showed a dramatic response in the hCD137 mice model inoculated with CT26 and EMT6 but not with 4T1 cell line. In a rechallenge study, no tumors grew in tumor-free mice previously treated with Urelumab, with effector memory T cells increased in peripheral blood, indicating Urelumab has a relatively long-lasting anti-tumor effect. The combination of Urelumab and anti-PD1 has a stronger tumor growth inhibition effect than that of anti-CD137 or anti-PD1 monotherapy on dual-target or triple target mice. These data show that the humanized CD137 mouse is a suitable model for evaluating the monotherapies or combination therapies targeting CD137. Citation Format: Yunlong Jiang, Tingting Gu, Weiwei Yu, Hongyan Sun, Mingkun Zhang, Juan Liang, Shuai Li, Cunxiang Ju, Jing Zhao, Xiang Gao, Mark W. Moore. CD137 humanized mice for preclinical efficacy evaluation of therapeutic antibodies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5623.

Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells.

Role of CD25+ dendritic cells in the generation of Th17 autoreactive T cells in autoimmune experimental uveitis

Immunotherapy with agonistic anti-CD137: two sides of a coin.

Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease

Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation

Abstract 5623: CD137 humanized mice for preclinical efficacy evaluation of therapeutic antibodies

Engagement of Toll-like Receptor 2 Enhances Interleukin (IL)-17(+) Autoreactive T Cell Responses Via P38 Mitogen-Activated Protein Kinase Signalling in Dendritic Cells.

Rapamycin Ameliorates Experimental Autoimmune Uveoretinitis By Inhibiting Thl/Th2/Th17 Cells And Upregulating Cd4+Cd25+Foxp3 Regulatory T Cells

Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy

Research on the effects of CD137 signaling on the function of CD3−CD56+NK cells

CD11b(high) CD11c(low) Ia(low) DCs Regulate T-cells Activation in the Experimental Autoimmune Uveitis

Soluble CD83 Alleviates Experimental Autoimmune Uveitis by Inhibiting Filamentous Actin-Dependent Calcium Release in Dendritic Cells.

CD137 Enhances Cytotoxicity of CD3(+)CD56(+) Cells and Their Capacities to Induce CD4(+) Th1 Responses.

CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development

Treatment of experimental autoimmune uveoretinitis with anti-tumor necrosis factor-α monoclonal antibody

Lymphotoxin beta receptor-Ig fusion protein treatment blocks actively induced, but not adoptively transferred, uveitis in Lewis rats.

Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis

Lymphotoxin β receptor-Ig fusion protein treatment blocks actively induced, but not adoptively transferred, uveitis in Lewis rats

CD83+ B cells alleviate uveitis through inhibiting DCs by sCD83

Apolipoprotein A1 Modulates Teff/Treg Balance Through Scavenger Receptor Class B Type I-Dependent Mechanisms in Experimental Autoimmune Uveitis.

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines